Search

Search Constraints

You searched for: Author/Creator Sethi, Supreet

Search Results

2. Assessment of humoral and cellular immune responses to SARS CoV‐2 vaccination (BNT162b2) in immunocompromised renal allograft recipients. Issue 2 (3rd March 2022)

3. CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL) TREATMENT OF PATIENTS WITH CHRONIC & ACTIVE ANTIBODY-MEDIATED REJECTION POST-KIDNEY TRANSPLANTATION (NCT03380377). Issue 3 (September 2020)

4. CLAZAKIZUMAB (ANTI-IL-6) INDUCES FOXP3+ TREGS IN HIGHLY HLA SENSITIZED PATIENTS RECEIVING HLAI KIDNEY TRANSPLANTATION (NCT03380962). Issue 3 (September 2020)

5. Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. Issue 4 (30th December 2021)

6. CLAZAKIZUMAB® (ANTI-IL-6) FOR DESENSITIZATION OF HIGHLY-HLA SENSITIZED PATIENTS AWAITING KIDNEY TRANSPLANT (NCT03380962). Issue 3 (September 2020)

8. Divergent Immune Responses to SARS-CoV-2 Vaccines in Immunocompromised Patients. Issue 1 (20th September 2021)

9. Divergent Immune Responses to SARS-CoV-2 Vaccines in Immunocompromised Patients. Issue 1 (January 2022)

10. Donor-derived Cell-free DNA Combined With Histology Improves Prediction of Estimated Glomerular Filtration Rate Over Time in Kidney Transplant Recipients Compared With Histology Alone. Issue 8 (August 2020)